99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System:...
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAESAREA, Israel, July...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation...
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth...
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference:...
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®...
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter...
U.S. index futures are showing mixed performance in pre-market trading this Tuesday, as investors await the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.